We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

INSTRUMENTATION LAB

  Platinum Instrumentation Laboratory provides diagnostic instruments for critical care and hemostasis to meet the testing needs... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Anticoagulant Adjustment Evaluated Using Different Prothrombin Time Tests

By LabMedica International staff writers
Posted on 26 Nov 2020
Print article
Image: HemosIL RecombiPlasTin 2G assay: A high sensitivity thromboplastin reagent based on recombinant human tissue factor (RTF) for the quantitative determination in human citrated plasma of Prothrombin Time (Photo courtesy of Instrumentation Laboratories).
Image: HemosIL RecombiPlasTin 2G assay: A high sensitivity thromboplastin reagent based on recombinant human tissue factor (RTF) for the quantitative determination in human citrated plasma of Prothrombin Time (Photo courtesy of Instrumentation Laboratories).
Preanalytical variables may affect the results of routine coagulation assays. One important variable is hematocrit (Ht), which affects coagulation testing results. A sample with high Ht has lower plasma quantity, resulting in a dilution effect on the sample by an excess of the anticoagulant sodium citrate.

The prothrombin time/international normalized ratio (PT/INR) test is the assay used to monitor dose-adjustments of vitamin K antagonist (VKA) treatment. Thus, for patients on monitored oral anticoagulant therapy who present an elevated Ht, adjustment of sodium citrate volume is essential, otherwise, these patients would have an incorrect diagnosis or treatment.

Clinical Laboratory Scientists at the Universidade de Sao Paulo (Sao Paulo, Brazil) enrolled 181 patients from the pulmonary hypertension ambulatory group with elevated Ht (>55%) and on warfarin therapy. All patients were diagnosed with polycythemia due to pulmonary hypertension and received anticoagulation treatment at the anticoagulation ambulatory center.

Paired citrate-adjusted and unadjusted blood specimens were tested using the PT test using two different thromboplastin reagents that are routinely used in their laboratory: the first was the HemosIL RecombiPlasTin 2G, with a thromboplastin (International Sensitivity Index [ISI] 1.00) of lyophilized recombinant human tissue factor (RTF), and the second reagent was HemosIL PT-Fibrinogen HS Plus with a thromboplastin (ISI 1.24) lyophilized from rabbit brain extract (HS Plus). Both reagents were produced by Instrumentation Laboratories (Bedford, MA, USA). The results are expressed as the international normalized ratio (INR). The correlation and percent change (% change) between sample pairs were calculated.

The scientists reported that the INR-RTF results from adjusted and unadjusted citrate blood specimens showed a strong correlation. The INR median was 2.25 for citrate-adjusted samples and was 2.22 for citrate-unadjusted samples. For samples with Ht >62%, the % change between sample pairs was >10%. Results using HS Plus showed a moderate correlation between citrate-adjusted and unadjusted samples. The INR median was 2.51 for citrate-adjusted samples and 3.45 for citrate-unadjusted samples. For samples with Ht>55%, the % change between sample pairs was higher than 10%.

The authors concluded that the adjustment of citrate concentration in samples with markedly elevated hematocrit depends on the PT reagent used in the routine tests, and each laboratory must perform a validation assay. Their data suggest that with RecombiPlasTin 2G reagent, samples of patients with polycythemia on warfarin therapy with Ht up to 62% could be obtained in an unadjusted citrate concentration tube. Using this PT reagent, can reduce the number of collection tubes and length of patient stay and avoid recall of patients, meaning lower treatment costs and faster patient care. The study was published in the November. 2020 issue of the journal Practical Laboratory Medicine.

Related Links:
Universidade de Sao Paulo
Instrumentation Laboratories

Print article

Channels

Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.